You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

95 Results
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Drugs Used:
gemcitabine,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CISplatin,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
prednisone,
vinCRIStine,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
ODB - General Benefit
    cyclophosphamide - oral tablets
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
prednisone,
vinCRIStine,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Adjuvant
Drugs Used:
pemetrexed,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Rare Diseases, 
Sarcoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
DOXOrubicin,
vinCRIStine,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Guidelines and Advice
Status: Current
ID: GL 3-20
Version: N/A
Aug 2019
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
CISplatin,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019
Regimen
Cancer Type:
Sarcoma, 
Osteogenic / Bone
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Neoadjuvant, Palliative
Drugs Used:
DOXOrubicin,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
CISplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2019

Pages